Replies to post #214524 on Biotech Values

[DewDiligence]

Another company (private) developing an FXR agonist for NASH:

https://www.prnewswire.com/news-releases/metacrine-completes-series-b-financing-to-advance-best-in-class-fxr-program-into-clinical-development-300568144.html

https://endpts.com/rich-heymans-metacrine-grabs-a-22m-round-in-search-of-a-superior-nash-drug

[DewDiligence]

Jim: I think Evercore/ISI is a little arrogant for suggesting that the various companies pursing FXR agonists for NASH are out to lunch. Time will tell.

p.s. Congratulations on your MDGL gains to date!

[DewDiligence]

B-I licenses dual-acting NASH candidate from Korea’s Yuhan:

https://www.businesswire.com/news/home/20190701005465/en

Under the terms of the agreement Yuhan Corporation will receive an upfront and near term payments of USD 40 million and is eligible to receive up to USD 830 million in potential milestone payments plus tiered royalties on future net sales.

…Preclinical evidence suggests high efficacy, when combining the gut-derived hormone GLP-1 with FGF21. The dual agonist (GLP1R/FGF21R agonist) is expected to reduce liver cell injury and hepatic inflammation by resolution of steatohepatitis as well as having direct antifibrotic effects and complements Boehringer Ingelheim’s R&D portfolio in NASH adding another potential first-in-class opportunity.